Publikationsdatenbank

Verbessert die zehntägige Inhalationstherapie mit einem Fluticason-Salmeterol-Kombinationspräparat klinische Symptome bei Pferden mit equinem Asthma? (2019)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Lehmann, Beatrice (WE 17)

Ladendorf, Ina (WE 17)

Doherr, Marcus G (WE 16)

Barton, Ann Kristin (WE 17)

Gehlen, H. (WE 17)

Quelle

Pferdeheilkunde : offizielles Organ der DVG, Fachgruppe Pferdekrankheiten = Equine medicine

Bandzählung: 35

Heftzählung: 2

Seiten: 153 – 158

ISSN: 0177-7726

Verweise

URL (Volltext): http://www.hippiatrika.com/download.htm?id=20190208

DOI: 10.21836/PEM20190208

Kontakt

Pferdeklinik

Oertzenweg 19 b
14163 Berlin
+49 30 838 62299 / 62300
pferdeklinik@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Equine asthma is a common respiratory disease of stabled horses and is characterized by dust-induced inflammation of the lower respiratory tract, bronchospasm and remodeling of lung tissue. The use of metered dose inhalers (glucocorticoids and sympathomimetic drugs) has been proven over the past years to be a safe and successful treatment. Several medical trials with human asthma patients have indicated that a combination product containing both fluticasone and salmeterol is superior to the respective monotherapies, concerning both its control of the clinical symptoms as well as the glucocorticoid dose required. This can most likely be attributed to the synergistic effect of both agents when used in combination. In the present study, ten horses with equine asthma, seven of which were experiencing acute exacerbation, were treated twice daily for ten days with a metered dose inhaler containing a combination product (4 microgram/kg fluticasone, 25 microgram salmeterol per actuation) and a spacer. All horses demonstrated a significant improvement of the clinical score, including the auscultatory findings, endoscopic findings, partial pressure of oxygen and percentage of neutrophil granulocytes in the bronchoalveolar lavage fluid. To what extent combination preparations outclass the monopreparations as an emergency and long-term therapy in horses with equine asthma must be clarified in further studies. The promising results of the present study should serve as an incentive to promote the approval of such a combination preparation for the treatment of equine asthma in order to allow its unrestricted use in horses.